News
Stay up-to-date on ReadyCell’s latest news, projects and developments.
ReadyCell is attending the 4th Brain Barriers Summit in Boston
Our ReadyCell sales representative Carla Sapienza will travel next August 29th, 30th and 31st to Boston to attend the Brain Barriers Summit, an event that aims to join industry experts through a discursive forum and evaluate how neuropharmaceuticals can be targeted.
New hyperoxia drug study references CacoReady Kits
The publication, entitled Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia, was aimed at testing the efficacy of three types of Thiazolidenoides (TZN) in preterm rabbits with bronchopulmonary dysplasia.
Hepatic drug elimination: The role of OATPs and MRP2 transporters
OATP1B1 and OATP1B3 are two influx transporters of the SLCO gene family that are primarily expressed in the sinusoidal membrane of hepatocytes.
New ICH M12 guideline for the regulation of drug interaction studies
Last month, the ICH launched a draft on Drug Interaction Studies regulatory. The guideline includes the regulations of the European, American and Japanese medical agencies and covers both in vitro and clinical studies.
Renal elimination of drugs: The role of kidney transporters
Understanding the role of these transporters in the clearance of new molecular entities (NME) is normally performed in-vitro at the early stages of drug development.
A ReadyCell & SOLVO Biotechnology meeting is taking place in Barcelona
We are happy to have with us Csenge Barabás, Nóra Kovács, Joseph Zolnerciksand and Dávid Bajkó to discuss a range of topics and to visit our facilities.
ReadyCell at the IX BiotechHealth Annual Symposium
ReadyCell will support academic research through its sponsorship at the IX BiotechHealth Symposium, which will be held on 28 June in Porto.
Caco-2 based in vitro models for the screening of anti-inflammatory drugs
Inflammatory reactions of the intestinal tract are the result of a combination of hereditary, genetic and/or environmental factors that have been clustered in the inflammatory bowel disease (IBD). ReadyCell has available CacoReady and CacoGoblet to assay compounds inflammatory properties.
Cell-based in vitro models to characterize Food-Drug Interactions
It is well known that food intake changes luminal conditions (e.g. pH, motility, microbiota,…) in the stomach and the small intestine, modifying drugs bioavailability. Food-drug interactions are one of the major challenges for oral-administered drugs, even more so if considering the growing use of food supplements and functional foods.
Job offer: Digital Communications Officer
To be successful in this role, you will need a deep understanding of the pharmaceutical industry. You will also need excellent written communication skills. An outstanding candidate will be someone whose expertise translates into increased brand awareness and profitability.